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Abstract
 
The product of the protooncogene 
 
Vav1
 
 participates in multiple signaling pathways and is a
critical regulator of antigen–receptor signaling in B and T lymphocytes, but its role during in
vivo natural killer (NK) cell differentiation is not known. Here we have studied NK cell devel-
opment in 
 
Vav1
 

 
/
 

 
 mice and found that, in contrast to T and NK-T cells, the absolute num-
bers of phenotypically mature NK cells were not reduced. 
 
Vav1
 

 
/
 

 
 mice produced normal
amounts of interferon (IFN)-
 

 
 in response to 
 
Listeria monocytogenes 
 
and controlled early infec-
tion but showed reduced tumor clearance in vivo. In vitro stimulation of surface receptors in
 
Vav1
 

 
/
 

 
 NK cells resulted in normal IFN-
 

 
 production but reduced tumor cell lysis. Vav1 was
found to control activation of extracellular signal-regulated kinases and exocytosis of cytotoxic
granules. In contrast, conjugate formation appeared to be only mildly affected, and calcium
mobilization was normal in 
 
Vav1
 

 
/
 

 
 NK cells. These results highlight fundamental differences
between proximal signaling events in T and NK cells and suggest a functional dichotomy for
Vav1 in NK cells: a role in cytotoxicity but not for IFN-
 

 
 production.
Key words: tumor clearance • 
 
Listeria
 
 infection • exocytosis • lymphoid development • 
cytokines
 
Introduction
 
The protooncogene 
 
Vav1
 
 is one of three members of the
Vav family of guanine nucleotide exchange factors (GEFs)
 
1
 
for the small GTPases of the Rho family (1). Its product,
p95
 
vav1
 
 (or Vav1) contains an array of structural motifs in-
cluding a Dbl homology domain, a single Src homology
(SH)2 and two SH3 domains, a pleckstrin homology do-
main, and a calponin homology domain, enabling it to in-
teract with different proteins involved in multiple signal
transduction pathways (1). Vav1 is expressed preferentially
in hematopoietic cells (2) and is rapidly phosphorylated af-
ter stimulation of growth factor receptors and Ag receptors
on B and T lymphocytes (3–5). Upon tyrosine phosphory-
lation, Vav1 promotes Rac1 and other Rho family proteins
to their active GTP-bound state (6–10), thereby mediating
vital functions such as survival, differentiation, motility, and
cell division (1, 11). In lymphocytes, activation of the small
Rho family proteins by Vav1 promotes Ag–receptor cap-
ping, actin polymerization, and Ag-induced proliferation of
B and T cells in vitro and effective T cell selection in vivo
(5, 12–17). Therefore, it is clear that Vav1 is essential for T
cell development and for Ag–receptor-induced responses
of B and T lymphocytes. In contrast, signaling require-
ments for NK cell development are not fully appreciated,
although soluble growth factors (including Flt3L/Flk2L,
stem cell factor [SCF], IL-7, and IL-15, which appear to be
the dominant cytokines) and stromal elements in the bone
marrow are essential (18–22). Because Vav1 has been re-
ported to be part of the signaling pathways activated by the
receptors for Flt3L/Flk2L and SCF (23, 24), it may be cru-
cial in early NK cell development.
Vav1 may participate in signaling pathways during the
activation of NK cells. Proximal events, including phosphor-
ylation of phosphatidylinositol 3 kinase (PI3K) and phos-
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Abbreviations used in this paper: 
 
ADCC, antibody-dependent cell cy-
totoxicity; ERK, extracellular signal-regulated kinase; GEFs, guanine
nucleotide exchange factors; 
 
L.m.
 
, 
 
Listeria monocytogenes
 
; MAPK, mito-
gen-activated protein kinase; PI3K, phosphatidylinositol 3 kinase; PLC,
phospholipase C.
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pholipase C (PLC), participate to sustain the rise in intracel-
lular calcium, a necessary second messenger during NK cell
effector functions (25). In T cells, Vav1 is a critical trans-
ducer of TCR signals to the calcium pathway, and in its ab-
sence, T cells fail to initiate IL-2 gene transcription and pro-
liferate (26). Vav1 has the ability to bind and be regulated
by the lipid substrates and products of PI3K (27). Vav1 has
also been proposed to enhance the production of substrates
for PLC
 

 
2 through activation of phosphatidylinositol 4-phos-
phate 5 kinase (28). In line with this, the PI3K-specific in-
hibitor wortmannin abolishes antibody-dependent cell cy-
totoxicity
 
 
 
(ADCC; reference 29), and mice deficient for
PLC
 

 
1 have decreased natural cytotoxicity (30).
Vav1 is phosphorylated upon contact with tumor targets
and upon cross-linking of the sole FcR (Fc
 

 
RII/III, CD16)
expressed by NK cells (31, 32) and therefore may be re-
quired for NK cell functions. Virally infected cells produce
IFN-
 

 
/
 

 
, which are potent activators of NK cells and have
been shown to induce phosphorylation of Vav1 in several
hematopoietic lineages, including lymphocytes (33).
Binding of NK cells to tumor cells and stimulation of
NK cells via CD16 results in activation of the mitogen-acti-
vated protein kinase (MAPK) cascades. One of this cas-
cades, the extracellular signal-regulated kinase (ERK) is
part of the intracellular signaling leading to IFN-
 

 
 produc-
tion, granule exocytosis, and cytotoxicity by NK cells (34–
36). In T cells, Vav1 is required to transduce TCR signals
to the ERK pathway (26), thereby mediating gene tran-
scription. By analogy, Vav1 may be involved in the process
of IFN-
 

 
 production in NK cells. On the other hand, p38
MAPK is also activated upon binding of NK cells to tumor
targets and leads to cytokine production and cytotoxicity
(37). However, Vav1 does not seem to be an essential reg-
ulator either of the p38 MAPKs or of the c-Jun NH
 
2
 
-ter-
minal kinase (JNK, or stress-activated kinase, SAPK) in T
cells (15, 16, 26).
Inactivation of the Vav1/Rac1 pathway in human NK
cell lines has helped address the role of Vav1 in NK cell
functions. As such, Vav1 has been shown to be critical for
signaling through CD16 and through the receptor(s) medi-
ating natural cytotoxicity (32, 38). In these studies, it was
reported that natural cytotoxicity and ADCC were both
decreased in human NK cell lines in the presence of a
dominant-negative form of Rac1 (32), or antisense oligo-
nucleotides for Vav1 (38). However, whether deficiency in
Vav1 will affect NK cell ontogeny or cytokine production
has not yet been investigated. Here, we characterize NK
cell differentiation in 
 
Vav1
 

 
/
 

 
 mice.
 
Materials and Methods
 
Mice. Vav1
 

 
/
 

 
 mice on the B10.BR background were de-
rived as described (14). 
 
Vav1
 

 
/
 

 
, B10.BR (
 
wt
 
), 
 
Rag2/
 

 
c
 

 
/
 

 
 (39),
and 
 
Rag2
 

 
/
 

 
 mice (40) were housed at the animal facility of the
Pasteur Institute.
 
FACS
 
®
 
 Analysis and Cell Sorting.
 
Cell suspensions were pre-
pared from spleen, thymus, liver, and bone marrow. They were
depleted of red cells and stained for flow cytometry as described
 
(39). mAbs directly conjugated to FITC, PE, Tricolor (TRI), al-
lophycocyanin, or biotin included mAbs specific for CD3, CD4,
CD8, CD11a (LFA-1), CD11b (Mac-1), CD19, CD45R (B220),
CD90 (Thy-1.2), CD117 (c-kit), CD122 (IL-2R
 

 
), CD161
(NK1.1), DX5, 2B4, Ly49A, Ly49C/I, Ly49D, Ly49G2, TCR-
 

 
, IgM (all from PharMingen), and H-2K
 
k
 
 (Caltag Laborato-
ries). Biotin-conjugated mAbs were revealed by streptavidin–
TRI (Caltag). Cells (10
 
6
 
) were first incubated with anti-Fc
 

 
RII/
III (hybridoma 2.4G2) for 20 min on ice to avoid unspecific
binding to low-affinity FcRs. To purify cells, splenocyte suspen-
sions were stained with mAbs specific for NK1.1–PE and CD3–
FITC: CD3
 

 
NK1.1
 

 
 NK cells and CD3
 

 
NK1.1
 

 
 T cells were
sorted using a FACStar™ (Becton Dickinson). The purity of the
sorted populations was reproducibly 
 

 
95%. Alternatively, sple-
nocytes were passed over nylon wool columns to deplete myeloid
and B cells and thereafter depleted of T cells by panning on anti–
TCR-
 

 
 (clone H57) coated Optilux
 
®
 
 Petri dishes (Falcon). Cells
were then expanded in IL-2 (1,000 U/ml) for 7–10 d.
 
In Vivo NK Cell Functions.
 
A standard lung clearance assay
was used to test the ability of mice to reject tumors in vivo as de-
scribed (41). Briefly, RMA-S cells (10
 
6
 
) were labeled in 100 
 
	
 
Ci
of 
 
51
 
Cr for 1 h at 37
 


 
C, and after several washings, 10
 
5
 
 cells per
mouse were injected intravenously. 4 h later, mice were killed,
and the residual radioactivity was measured in the explanted lungs.
In a typical experiment, total radioactivity of the injected inocu-
lum (10
 
5
 
 cells/200 
 
	
 
l) would be 
 

 
25–50,000 cpm. In a second
tumor model, modified from that described in reference 43,
RMA-S cells (2.5 
 

 
 10
 
5
 
) were injected intraperitoneally, and 48 h
later the peritoneal exudate cells recovered, counted, and stained
with mAbs specific for CD3, NK1.1, and H-2K
 
k
 
. Residual tumor
cells could readily be distinguished by their larger size, CD3 stain-
ing, and absence of H-2K
 
k 
 
staining. In the lymphoma metastases
model, mice were injected intravenously with H-2–compatible
(H-2
 
k
 
) but class I
 
low
 
 RDM4 cells (10
 
4
 
), and survival was scored for
up to 14 d. Those mice that survived were killed at day 14 and
their livers fixed in Bouin’s medium for 48 h. Macroscopic me-
tastases were readily detected by visual inspection. For the infec-
tion model, 10
 
4
 
 
 
Listeria monocytogenes
 
 (
 
L.m.
 
) bacteria (strain LO28)
were injected intravenously, and 48 h later the serum was col-
lected from each mouse and the IFN-
 

 
 content was quantified by
ELISA (Genzyme). Bacterial burden in livers and spleens was de-
termined 48 h after injection as described previously (42).
 
In Vitro NK Cell Cytotoxicity.
 
A standard 
 
51
 
Cr-release assay
was used to measure NK activity in vitro as described (43). Tar-
get cells (H-2
 
a
 
 murine YAC-1 thymoma, H-2
 
b
 
 murine macro-
phage tumor line IC-21, H-2
 
b
 
 murine EL-4 thymoma, H-2
 
d
 
 mu-
rine P815 mastocytoma, Con A–activated B10.BR and 
 

 
2m
 

 
/
 

 
blasts, and H-2
 
b
 
 murine lymphomas RMA and transporter associ-
ated with antigen processing [TAP]-deficient RMA-S) were la-
beled with 100 
 
	
 
Ci 
 
51
 
Cr (ICN Pharmaceuticals), and 2.5–5 
 

 
10
 
3
 
 targets were incubated with graded numbers of effector cells
in 200 
 
	
 
l of medium for 4 h. For natural cytotoxicity, effector
cells were NK-enriched splenocytes (by passage on nylon wool
columns) from untreated mice or from mice primed 40 h earlier
with 0.2 mg of poly(I:C) (Sigma-Aldrich). NK-enriched spleno-
cytes and FACS
 
®
 
-purified NK cells were expanded in IL-2
(1,000 U/ml) for 7–10 d and thereafter used as effectors for (a)
ADCC using EL-4 cells coated with anti–Thy-1.1 mAb (lysis of
EL4 cells without the Ab never exceeded 10% at the highest E/T
ratios); (b) “reverse” ADCC (R-ADCC) using FcR
 

 
 P815 cells
in presence or absence of anti-NK1.1, anti-2B4, or anti-CD16
mAbs; (c) MHC inhibition and recognition of “missing self” us-
ing Con A–activated B10.BR and 
 

 
2m
 

 
/
 

 
 blasts or RMA and
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RMA-S cells. MHC class I
 

 
 Con A blasts (
 
wt
 
) or MHC class I
 

 
RMA cells were both resistant to lysis (
 

 
5%), even at the highest
E/T ratios. Radioactivity released into the cell-free supernatant
was measured, and the percent specific lysis was calculated as fol-
lowing: 100 
 

 
 (experimental release 
 

 
 spontaneous release)/
(maximum release  spontaneous release).
In Vitro Cytokine Production. Sorted NK cells (2  104 cells/
200 	l) were cultured in flat-bottomed microtiter plates in hu-
man IL-2 (1,000 U/ml) and stimulated with murine IL-12 (2 ng/
ml; PeproTech) or mAbs specific for NK1.1 (clone PK136, 20
	g/ml), 2B4 (5 	g/ml), CD16 (75 	g/ml), or control anti–Gr-1
mAb (10 	g/ml). Wells were precoated with mAbs (50 	l/well)
for 4 h before adding NK cells. After 24 h, the cell-free superna-
tants were collected and the amount of IFN- was quantitated by
ELISA (Genzyme). In parallel experiments, FACS®-purified NK
and T cells (2  105) were incubated in the presence of brefeldin
A (10 	g/ml) for 4 h at 37
C on flat-bottomed microtiter plates
precoated with anti-NK1.1 or anti-CD3. Cells were then
washed, fixed in 2% paraformaldehyde for 30 min on ice, thereaf-
ter stained with anti-IFN-–FITC (PharMingen) in 0.5% sapo-
nin. As controls, cells were incubated in medium alone or with
PMA (50 ng/ml) and ionomycin (1 	g/ml).
Conjugate Formation. IL-2–activated NK cells (2  105) were
labeled with 1 	g/ml of 2-7-biscarboxyethyl-5(6)-carboxyfluo-
rescein (BCECF; Calbiochem) for 30 min at room temperature,
washed, and mixed with a 1:1 ratio of YAC-1 targets that had
been labeled with 40 	g/ml of hydroethydine (HE; Polysciences,
Inc.) for 10 min at room temperature. Cell mix was spun at 1,000
rpm for 5 min and incubated for 1, 2, 5, 10, or 20 min at 37
C.
After gentle resuspension, cells were analyzed by flow cytometry.
BCECF emits in FL1 and HE emits in FL3, therefore conjugates
can be readily detected as double positive (FL1/FL3). Controls
were sham conjugates obtained by centrifuging and incubating
under the same conditions differentially labeled (HE and
BCECF) YAC-1 cells. Background double-positive staining was
reproducibly 1%.
Calcium Flux. Purified NK and T cells were labeled with 5
	g/ml of Indo-1 (Molecular Probes) for 45 min at 37
C. Washed
cells were resuspended in 10% RPMI and divided into aliquots (5 
105 cells each) that were incubated for 30 min at 4
C with 20
	g/ml of one of the following mAbs: anti-2B4, anti-NK1.1,
anti-CD16, anti-Ly49D, or anti-CD3. Cells were then washed
and kept at room temperature until analysis, which was done us-
ing an LSR flow cytometer (Becton Dickinson). Immediately be-
fore acquisition, cells were resuspended in 500 	l of prewarmed
medium. Acquisition was performed for 45 s to set the baseline
and then briefly interrupted to add 25 	g/ml of goat F(ab)2 anti–
mouse IgG to cross-link anti-2B4 and anti-NK1.1 mAbs or goat
F(ab)2 anti–rat IgG to cross-link anti-CD16, anti-Ly49D, or
anti-CD3 mAbs, and finally interrupted after 4–5 min to stimu-
late cells with 1 	g/ml of ionomycin. Cross-linking Abs failed to
generate calcium flux in Indo-1–labeled cells not preincubated
with primary mAbs.
ERK Activation. NK and T sorted cells were first expanded
in IL-2. Before analysis, cells were starved in IL-2–free medium
for 4 h at 37
C and thereafter incubated on ice for 30 min with
20 	g/ml of anti-NK1.1 or anti-CD3 mAbs, followed by cross-
linking with the relevant F(ab)2 Ab for 3 min at 37
C. As a posi-
Figure 1. Vav1 is dispensable
for NK cell development. (A) Cells
from spleen, marrow, and liver
were stained with -CD3FITC
and -NK1.1PE mAbs. Thy-
mocytes were stained with
-CD3FITC, -NK1.1PE, and
-HSABIO mAb, and a gate was
set to exclude HSA immature
cells. Figures in the dot plots in-
dicate percentages of NK, NK-T,
and T cells. Data are from one
representative of eight indepen-
dent experiments. (B) Spleen cells
were stained with -NK1.1PE,
-TCR-BIO, and -CD19BIO
and one of the indicated FITC-
conjugated mAbs. Biotinylated
Abs were revealed with strepta-
vidin–TRI, and only NK1.1
TCR-CD19 NK cells
were included in the analysis.
Figures show percentage of NK
cells staining positive for FITC.
No significant differences were
detected between wt and Vav1/
NK cells. Results are from one
representative of five indepen-
dent experiments.
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tive control, cells were stimulated with 50 ng/ml PMA for 15
min at 37
C. Cells were lysed in 1% NP-40–containing buffer as
described (44), and soluble proteins were separated by SDS-
PAGE. ERK activation was assessed by immunoblotting with the
anti–phospho-ERK mAb E4 (Santa Cruz Biotechnology). The
amount of ERK proteins was assessed by reprobing the same
membrane with a polyclonal anti-ERK Ab (Santa Cruz Biotech-
nology). Autoradiographies were quantified by densitometry.
Granule Exocytosis. IL-2–activated NK cells were mixed with
YAC-1 cells at a 2:1 ratio. After 4 h, the specific release of es-
terase was measured in 25 	l of cell-free supernatants after addi-
tion of 175 	l of PBS containing 0.22 mM of DNP (Sigma-Aldrich)
and 0.2 mM of N--benzyloxycarbonyl-l-lysine thiobenzyl ester
(BLT; Sigma-Aldrich) as described (44). Maximal release was ob-
tained by measuring the esterase content in the supernatant of
NK cells after three freeze–thaw cycles.
Statistics. Statistical significance of data was evaluated by ap-
plying Student’s t test (Microsoft Excel® software).
Results
Vav1 Is Not Required for NK Cell Development but Is Es-
sential for T and NK-T Cell Development. We enumerated
lymphocyte subsets in the spleen, bone marrow, liver, and
thymus of Vav1/ mice and littermate controls (Vav1/
or Vav1/, hereafter referred to as wt). While T and NK-T
cells were reduced in Vav1/ mice, NK cell percentages
and absolute numbers in the spleen and bone marrow of
Vav1/ mice were found to be greater than in controls
(Fig. 1 A and Table I). Mature NK cells express a constella-
tion of surface markers, including members of the Ly49
family of MHC receptors, whose upregulation starts at 10 d
of age and reaches levels comparable to those of mature
NK cells at 2–3 wk of age (45). We found that the expres-
sion pattern of 13 different markers on splenic and marrow
NK cells (including Ly49A, Ly49C/I, Ly49D, Ly49G2,
2B4, DX5, CD2, CD11b, CD16, CD69, CD90, CD117,
and CD122; Fig. 1 B and data not shown) was comparable
between Vav1/ and wt NK cells. Therefore, Vav1 is not
required for NK cell development, unlike T and NK-T
cell development.
Vav1 Regulates NK Cell–mediated Tumor Clearance. NK cells
recognize cells with disparate class I MHC expression and
rapidly kill tumor cells that have lost expression of MHC
class I (46). This function can be evaluated in vivo using a
short-term assay, where radiolabeled RMA-S (class I–nega-
tive) tumor cells are injected intravenously. NK cell antitu-
mor activity is inversely proportional to the radioactivity
measured in the lungs. This function is T cell independent,
because NK cell–depleted mice cannot reject the injected
tumor cells (41). Thus, NK cell–deficient Rag2/c/
mice retained 20% radioactivity, while only 1% was
found in wt mice (Fig. 2 A) or in Rag2/ mice (data not
shown). In contrast, Vav1/ mice displayed reduced NK
cell activity, as about three- to fourfold more radioactivity
was detected (3.4  1% in Vav1/ versus 0.9  0.2% in
wt; P  0.002).
In a second model of NK cell–dependent tumor rejec-
tion (47), we tested the capacity of Vav1/ mice to elimi-
nate intraperitoneally injected RMA-S cells. As shown in
Fig. 2 B, 60% of the injected tumor cells were retained in
NK cell–deficient Rag2/c/ mice. In contrast, only
0.5% of the inoculated cells were recovered in wt mice,
while Vav1/ mice retained 16-fold more cells (Fig. 2
B), showing a considerable disadvantage in controlling tu-
mor growth. Importantly, the absolute numbers of NK cells
in the peritoneal cavity of wt and Vav1/ mice were simi-
lar, and the injection of tumor cells induced a similar local
increase in NK cell numbers (data not shown). Finally, wt
and Vav1/ mice were injected with H-2–compatible (H-
2K) RDM4 lymphoma cells, which express low levels of
class I and therefore should be tolerated by T cells yet sensi-
tive to NK cell lysis. All wt mice (four of four) survived for
14 d after the inoculum, and no signs of liver metastases
were found at sacrifice (Table II). In contrast, three of five
Rag2/c/ mice succumbed during the 14-d period, and
the two surviving mice presented numerous liver me-
tastases. Vav1/ mice showed signs of NK cell deficiency,
as one of six mice died, and two of the remaining five mice
showed liver metastases at sacrifice. Collectively, these re-
sults show that Vav1/ mice have reduced NK cell–medi-
ated antitumor activity in vivo.
Vav1 Is Dispensable for the Early Control of L.m. Infec-
tion. NK cells can secrete cytokines (notably IFN-,
TNF-, and GM-CSF) during viral or bacterial infections
(48). Previous studies suggested that NK cell–derived IFN- is
critical for early control of infection by L.m. (49). There-
Table I. Lymphoid Subsets in Vav1/ Mice
n wt Vav1/
Spleen
Total lymphocytes 11 653  140 671  110
NK1.1CD3 NK cells 11 17  5 25  7
NK1.1CD3 NK-T cells 8 9.4  3 5.2  2
TCR- T cells 9 174  19 81  22
IgM B cells 10 415  130 533  92
Bone marrow 
Total lymphocytes 5 23.4  5.4 25.8  6.3
NK1.1CD3 NK cells 5 0.19  0.02 0.37  0.17
Liver
Total lymphocytes 7 27.4  9.6 10.4  1.7
NK1.1CD3 NK cells 7 1.75  0.5 1.41  0.5
NK1.1CD3 NK-T cells 7 6.2  0.6 1.1  1
Thymus
Total lymphocytes 9 587  126 100  63
NK1.1CD3 NK cells 9 0.54  0.4 0.8  0.4
NK1.1CD3 NK-T cells 9 5.0  0.24 0.42  0.14
Cell suspensions were enumerated and stained with a mixture of mAbs
specific for TCR-, IgM, and NK1.1. Absolute cell numbers were
calculated based on the percentages of positive cells out of the total
number of lymphoid cells. Statistically significant differences (P  0.05,
Student’s t test) are indicated in bold type. Splenocyte numbers are
expressed in 106, and for the other organs, cell numbers are expressed in 105.
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fore, we infected Vav1/ mice and wt mice intravenously
with 104 L.m., and bacterial burden was measured 48 h
later in the liver and spleen (Fig. 2 C). Controls included
Rag2/c/ and Rag2/ mice. NK cell–deficient animals
displayed an average of 10-fold more colonies in liver
and spleen (data not shown) as compared with wt mice
(P  0.002; Fig. 2 C) or Rag2/ mice (data not shown).
In contrast to the differences found between wt and Vav1/
mice in tumor clearance, no significant difference was
found between wt and Vav1/ mice in terms of bacterial
burden. Thus, Vav1/ mice can control the early phases
of L.m. infection. As IFN- appears an essential cytokine
for early control of L.m. infection, we measured the IFN-
levels in the sera of infected mice. Fig. 2 D shows that
IFN- production by Vav1/ infected mice was similar to
that of wt infected mice. Taken together, these results sug-
gest a functional dichotomy for NK cell functions: normal
tumoricidal activity is Vav1 dependent, while IFN- pro-
duction is Vav1 independent.
Vav1 Regulates Natural Cytotoxicity, ADCC, and Lysis Ini-
tiated by Distinct NK Cell Receptors but Is Dispensable for IFN-
Production In Vitro. To dissect the cellular mechanisms re-
sponsible for defects in Vav1/ NK cells in vivo, we com-
pared the lytic activity of freshly isolated and IL-2–activated
NK cells from Vav1/ and wt mice. As shown in Fig. 3,
A–E, target cell lysis by Vav1/ NK cells was defective,
ranging from 20 to 50% of control values. The assays in-
cluded: (a) natural cytotoxicity versus murine thymoma
cells (YAC-1), mastocytoma (P815), or macrophage cell
line (IC-21); (b) ADCC using EL4 cells precoated with
-CD90; (c) killing of class I–deficient cells (2m/ Con
A–activated blasts and TAP-deficient RMA-S thymomas);
and (d) “reverse” ADCC (R-ADCC) versus FcR P815
cells in the presence of -CD16, -2B4, or -NK1.1
mAbs. These results strongly suggest that all forms of NK
cell–mediated cytolysis depend on Vav1, irrespective of
which cellular receptor is activated. Importantly, prior acti-
vation of NK cells with poly(I:C) in vivo or with IL-2 in
vitro did not rescue the lytic defect in Vav1/ NK cells
(Fig. 3, B and D), and no significant difference was ob-
served in the proliferation induced by IL-2 (data not
shown).
In contrast, Vav1/ NK cells responded with normal
IFN- production (Fig. 4 A), after stimulation of 2B4,
CD16, and NK1.1 activating receptors, and with IL-12. It
should be noted that stimulation of Vav1/ NK cells via
the same receptors (2B4, CD16, and NK1.1) did not result
in normal cytotoxicity of FcR P815 cells (Fig. 3 E). To
better evaluate the dichotomy between cytokine produc-
tion and cytotoxicity observed in Vav1/ NK cells, we
measured the levels of intracellular IFN- produced by wt
and Vav1/ NK cells 4 h after activation. This can be
compared with the 4-h Cr-release assay used to measure
cytotoxicity. No significant defect in IFN- production
was detected, as similar percentages of wt and mutant NK
cells stained positively for intracellular IFN- upon NK1.1
stimulation (Fig. 4 B). In contrast, CD3 stimulation did not
result in IFN- production by Vav1/ T cells (Fig. 4 B).
Figure 2. Vav1 is required for antitumor activity but not
for antibacterial activity. (A) Mice (five wt, four Vav1/,
three Rag2/c/) were injected intravenously with 105
51Cr-labeled RMA-S cells. 4 h after injection, the residual
radioactivity was measured in the lungs and is expressed as
percentage of the total radioactivity. Data are representa-
tive of three separate experiments. (B) Mice (eight wt, five
Vav1/, six Rag2/c/) were injected intravenously
with 2.5  105 labeled RMA-S cells. 48 h after injection,
cells in the peritoneal exudate were collected, enumerated,
and stained with -CD3 and -H-2Kk. Residual RMA-S
cells were discriminated by virtue of size and surface phe-
notype (large CD3H-2K cells). (C) Mice (six wt, six
Vav1/, four Rag2/c/) were injected intravenously
with 104 L.m., and 48 h later liver CFUs were enumer-
ated. (D) The sera from mice infected with L.m. (10 wt, 11
Vav1/, 4 Rag2/c/) were collected after mice were
killed, and IFN- was detected by standard ELISA tech-
nique. P values (Student’s t test) are expressed for Vav1/
versus wt. White bars, Rag2/c/; black bars, wt; gray
bars, Vav1/.
Table II. Vav1/ Mice Have a Reduced Capacity to Clear 
Tumor Cells
wt Vav1/ Rag2/c/
Mortality 0/4 1/6 3/5
Liver metastases in 
surviving mice 0/4 2/5 2/2
Mice were injected intravenously with 104 lymphoma cells (RDM4,
H-2k, class Ilow), and survival was followed for 14 d. Those mice that
survived were killed and examined for the presence of liver metastases. 
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Vav1 Has Only a Minor Role in NK Cell Conjugate Forma-
tion. It has been shown that conjugate formation is de-
creased in human NK cell lines expressing a dominant-
negative form of the Vav1 substrate Rac1 (32). We there-
fore tested the ability of Vav1/ NK cells to form stable
conjugates using a flow cytometric approach. As shown in
Fig. 5 A, conjugate formation by Vav1/ NK cells was
readily detectable, ruling out an essential role for Vav1 in
this process. A detailed kinetic study revealed that Vav1/
NK cells formed somewhat less conjugates, although the
observed decrease never exceeded 30%, and was not statis-
tically significant in four of five time points analyzed (Fig. 5
Figure 3. Vav1 regulates NK cell cy-
totoxicity. (A) Splenocytes were en-
riched for NK cells by passage on nylon
wool columns, and percentages of NK
cells are shown for a representative ex-
periment. (B) NK-enriched splenocytes
from poly(I:C)-injected mice (squares)
or from untreated mice (triangles) were
used to test natural cytotoxicity versus
YAC-1 and IC-21 tumor targets at the
indicated NK/target ratios. (C) Spleno-
cytes were enriched for NK cells and
expanded in IL-2. The percentages of
NK cells are shown for a representative
experiment. (D) IL-2–activated NK
cells were tested for cytolytic activity
versus YAC-1, Con A–activated
B6.2m/ blasts, Tap/ RMA-S cells
(both MHC class I deficient); control
experiments included Con A–activated
wt blasts and RMA cells (both express-
ing normal levels of MHC class I). (E)
ADCC of Ab-coated EL4 cells and for
IL-2–activated NK cells were tested for
reverse ADCC of FcR P815 cells in
presence of the indicated Abs. Control
experiments included non–Ab-coated
EL4 and P815 cells. Each experiment is
representative of three.
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B). Therefore, although Vav1 may be required for normal
conjugate formation under these conditions, the extent of
the lytic defect (up to 80% reduction), strongly suggests
that postbinding mechanisms account for defective killer
activity of Vav1/ NK cells.
Vav1 Is Required to Initiate Calcium Flux in T Cells but Not
in NK Cells. Vav1 is required for normal calcium flux in
response to Ag–receptor signaling in T cells (26), and by
analogy, reduced cytolysis by Vav1/ NK cells could re-
sult from a similar defect in proximal signaling. To test this,
we compared the rise in intracellular calcium in NK cells
upon cross-linking membrane receptors. Normal calcium
flux was induced after stimulation of the NK1.1 and CD16
receptors (Fig. 6) as well as the 2B4 and Ly49D receptors
(data not shown) in both wt and Vav1/ NK cells. In con-
trast, and as expected from previous reports (26), CD3
cross-linking did not induce calcium flux in Vav1/ T
cells (Fig. 6). Thus, Vav1 is not essential to transduce sig-
nals to the calcium pathway in NK cells and acts down-
stream of the rise in intracellular calcium to control the NK
cell cytotoxicity machinery.
Vav1 Controls ERK Activation in NK and T Cells. Vav1
appears essential in transducing TCR signals to the ERK
pathway in T cells (26), although studies using T cells from
two other Vav1 mutant mice did not support an essential
role for Vav1 in ERK activation (15, 16). ERKs have been
implicated in the control of both cytotoxicity and IFN-
production by NK cells (34–36). We therefore analyzed
ERK1/2 phosphorylation in NK cells after stimulation of
NK1.1 and compared it to CD3-initiated ERK1/2 phos-
phorylation in T cells. We found a reduced activation of
ERK1 (eightfold) and ERK2 (2.5-fold) in Vav1/ T cells
(Fig. 7 A), confirming the essential role of Vav1 in TCR-
mediated ERK activation (26). NK1.1-mediated ERK1
phosphorylation was 4.4-fold reduced in Vav1/ NK
cells, while no significant reduction in activation of ERK2
Figure 4. Vav1 is dispensable
for NK cell–mediated IFN-
production. (A) Sorted IL-2–acti-
vated NK cells were incubated
with different plate-bound anti-
bodies or with IL-12. After 24 h,
the amount of IFN- produced
was measured by a standard
ELISA. One representative ex-
periment of two independent
experiments performed. (B)
Sorted IL-2–activated NK cells
were incubated at 37
C with
the indicated stimuli and there-
after stained for intracellular
IFN- content.
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was detected (Fig. 7 A). However, stimulation of Vav1/
NK cells via Ly49D resulted in reduced activation of both
ERK1 (threefold) and ERK2 (twofold) kinases (data not
shown). Collectively, these results suggest that Vav1 con-
trols the ERK pathway in NK cells.
Vav1 Controls Exocytosis of Cytotoxic Granules upon Target
Cell Binding. Intracellular polarization of NK cell cyto-
toxic granules toward sensitive target cells precedes granule
exocytosis. The Vav1/Rac1 pathway has been suggested to
be a critical regulator of this process (32). To directly mea-
sure granule exocytosis upon contact with targets, we
quantitated the granzyme A esterase content in the super-
natants of NK cell cultures stimulated with targets. Al-
though total esterase content was similar in wt and mutant
NK cells (data not shown), Vav1/ NK cells showed a sig-
nificant reduction in esterase exocytosis compared with wt
NK cells (7.2  4.5 versus 17.3  5%, P  0.03; Fig. 7 B).
Thus, the absence of Vav1 results in defective granule exo-
cytosis and reduced ability to lyse tumor targets.
Discussion
The data presented here show that Vav1 is an essential
regulator of NK cell–mediated cytolysis of tumor cells. On
the other hand, Vav1 is dispensable for NK cell develop-
ment and cytokine production. Thus, Vav1/ mice gen-
erate normal numbers of phenotypically mature NK cells
but show a dichotomy in NK cell–mediated effector func-
tions. They are competent for IFN-–dependent control of
early bacterial infections yet have a reduced capacity to re-
ject tumors. We could define the cellular mechanisms that
are Vav1 dependent. The absence of Vav1 had only minor
effects on conjugate formation, and calcium flux was nor-
mal. In contrast, the absence of Vav1 reduced ERK activa-
tion and exocytosis of cytotoxic granules that allow NK
cells to lyse their targets.
The phenotype of NK cell functions in Vav1/ mice is
reminiscent of that of Beige mice, the murine model for
Chediak-Higashi syndrome, a monogenic disease caused by
mutations in the lysosomal trafficking regulator (Lyst) gene
(50). Although the function of the Lyst protein has not yet
been fully understood, it has been suggested to interact
with microtubules to regulate protein sorting and late en-
dosomal organization (51). Whatever the mechanisms un-
derlying the Chediak-Higashi syndrome, the end result is a
severely impaired granule exocytosis, much like what we
have observed in Vav1/ NK cells. Interactions between
Figure 5. Vav1 plays a minor role in NK cell conjugate formation. (A)
BCECF-labeled NK cells were allowed to form conjugates with HE-
labeled YAC-1 targets for 20 min at 37
C and immediately analyzed by
flow cytometry. Double-positive cells are conjugates, and the percentages
(NK cells bound to targets out of the total NK cells) for the two genotypes
are indicated for one representative of six independent experiments. Non-
specific aggregates were reproducibly 1%. (B) Kinetics of conjugate for-
mation. Values at each time point were analyzed statistically, and signifi-
cant differences (P  0.05 by Student’s t test) are indicated by an asterisk.
Figure 6. T cells but not NK cells require Vav1
to initiate calcium flux. Purified NK cells and T
cells were stimulated with the primary mAbs (anti-
NK1.1, anti-CD16, or anti-CD3), and analysis was
done for 45 s to set the baseline levels of intracellular
calcium. Acquisition was interrupted once to add
cross-linking goat F(ab)2 Abs and again to add 1
	g/ml of ionomycin. Cells were analyzed by LSR-
FACS®. Intracellular calcium is proportional to the
FL5/FL4 ratio.
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Vav1 and Lyst have never been documented, but it is likely
that they both regulate components of the cytoskeleton
(actin filaments and microtubules, respectively) required for
successful exocytosis. However, NK cells of Beige mice
have a complete defect in cellular cytotoxity, whereas NK
cells of Vav1/ mice have reduced capacity to kill tumor
targets. How can we explain the quantitative defect in the
lytic activity of Vav1/ NK cells?
Cell-mediated cytotoxicity can be induced by calcium-
dependent, perforin-mediated mechanisms and calcium-inde-
pendent, FasL-mediated pathways (52). The residual cyto-
toxicity of Vav1/ NK cells could be accounted for
FasL-dependent mechanisms, which would not depend on
exocytosis. In fact, we found that target cell lysis was totally
abrogated in calcium-free medium in both wt and Vav1/
NK cells (data not shown), ruling out calcium-independent
mechanisms as responsible for the residual cytotoxic activ-
ity seen in Vav1/ NK cells.
Activation of small GTPases can be induced by several
GEFs, and functional redundancy among members of this
family may account for some degree of compensation in
the absence of Vav1. Human NK cells have been recently
shown to express Vav2, which regulates the development
of cell-mediated cytotoxicity (53). We have also detected
Vav2 proteins in murine NK cells by intracellular staining
(our unpublished observation), suggesting that suboptimal
granule exocytosis and residual cytolysis by Vav1/ NK
cells may be accounted for by compensatory mechanisms
(activation of Rac1 or Rho?) initiated by Vav2. The analy-
sis of NK cell functions in mice deficient for Vav1 and
Vav2 will help answer this question.
Inactivation of the Vav1 substrate Rac1 reduces the ca-
pacity of human NK cells to form stable conjugates with
target cells (32). However, our data indicate only a minor
role for Vav1 at this stage, suggesting essential roles for
Vav1 in postbinding target cell lysis. Moreover, GEFs other
than Vav1 may control Rac1-dependent conjugate forma-
tion, explaining the partial discrepancy between our results
and those reported in the literature (32).
Our data underscore fundamentally divergent roles for
Vav1 in the biology of T and NK lymphocytes. First, T
and NK-T cell development and T cell functions are im-
paired in Vav1/ mice, a consequence of the fact that T
cells must signal through the same (Ag) receptor to com-
plete differentiation and to exert their effector functions.
Instead, requirement for Vav1 in NK cell functions (at least
for cell-mediated cytotoxicity) dissociates from require-
ment for development. Several cytokine receptors are
thought to drive NK cell differentiation (i.e., Flt3, c-kit,
IL-7R, IL-15R), and we can suggest that Vav1 is not es-
sential for transducing signals through any of these recep-
tors, although it is phosphorylated upon ligation of some of
them (23, 24). Moreover, it is likely that NK cell cytotox-
icity is triggered by ligand–receptor systems different from
those required for development, otherwise developing NK
cells might be constitutively stimulated in the absence of
inhibitory signals (which develop only later in life) and po-
tentially dangerous.
Second, proximal signaling (measured by rise in intracel-
lular calcium) in Vav1/ NK cells is not impaired as op-
posed to defective capping and calcium flux upon cross-
linking of TCRs in Vav1/ T cells (14–16). Therefore,
the abnormal biological responses of Vav1/ T cells seem
to be due to defective cellular activation. Along these lines,
cytotoxic CD8 T cells of Vav1/ mice fail to generate a
primary response to viral infections, while they are able to
mount a normal CTL secondary response, suggesting that
Vav1 is required for T cell–mediated cytotoxicity only
when the activation threshold is high, during a primary re-
sponse (54). But this is unlikely to occur in Vav1/ NK
cells, as we show here that IL-2 activation in vitro and
stimulation with poly(I:C) in vivo does not rescue the NK
cell lytic defect. Although several receptors have been re-
ported to be able to activate NK cell effector functions (55),
the ones that activate natural cytotoxicity remain unknown
(56). This incomplete knowledge has obviously been an
obstacle for advancing our understanding of the molecular
mechanisms transducing NK cell activating signals into ef-
Figure 7. Vav1 controls ERK activation and granule exocyto-
sis. (A) Purified NK and T cells were incubated with the indi-
cated mAb and stimulated with cross-linking Abs. Cell lysates
were immunoblotted with an mAb specific for the phosphory-
lated forms of ERK1/2. Total amounts of inactive ERK1/2 were
assessed by polyclonal anti-ERK1/2. Stimulation with PMA gen-
erated comparable levels of phosphorylated ERK1/2 in wt and
Vav1/ cells. (B) Equal numbers of NK cells were stimulated
with YAC-1 targets for 2 h and 30 min at 37
C. Supernatants
were collected, and the specific release of esterase (granzyme A) was measured by using a BLT colorimetric assay, where the maximum release of esterase
was obtained by freezing and thawing NK cells. Mean values  SDs are shown from five independent experiments.
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fector functions (57). The NK cell receptors we have used
to elicit calcium flux (NK1.1, CD16, 2B4) are known to
enhance cytotoxicity, but it would be interesting to mea-
sure rise in intracellular calcium upon target cell binding.
Vav1 has been shown to control the ERK pathway in T
cells (26), using the same Vav1/ mice analyzed in this
study. However, two independent groups, using mice car-
rying different Vav1 mutations, did not find an essential
role for Vav1 in ERK activation (15, 16). We confirm here
the results by Costello et al. (26) showing that Vav1/ T
cells have a reduced ERK activation. Moreover, we show
that Vav1 controls the ERK pathway in NK cells. Al-
though both cytotoxicity and IFN- production have been
shown to depend on ERK (34–36), we found that only cy-
totoxicity was affected in Vav1/ NK cells. It is possible
that different thresholds of ERK phosphorylation control
cytokine productions and granule exocytosis, explaining
the divergent effect seen in Vav1/ NK cells.
Finally, receptor ligation in Vav1/ NK cells resulted in
divergent effects on tumor cell killing and on cytokine pro-
duction, showing that Vav1 differentially controls NK cell
effector functions. This situation is not paralleled in T cells,
where TCR-initiated events tested so far (calcium flux,
proliferation, apoptosis, IL-2 gene transcription, cytotoxic-
ity) are all defective in the absence of Vav1 (14–16, 26).
Our results are consistent with a functional dichotomy in
NK cell signaling with respect to Vav1, where Vav1-
dependent cytotoxicity contrasts with Vav1-independent
cytokine production.
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